Growth

Sermorelin Acetate

Peptide · GHRH(1–29) sequence · 29 amino acids

FDA · APPROVED (GEREF — DISCONTINUED)

Half-life

~15 minutes

Very short

minsdays

Route

SubQ injection

Evidence

Approved therapeutic

Risk

Standard

Overview

Known for

GHRH analogue. One of the oldest and most studied GH secretagogues. Gentler than CJC-1295. FDA-approved for GH deficiency diagnosis. Good entry-level GH peptide with extensive safety data.

Mechanism

First 29 amino acids of natural GHRH. Stimulates GH release naturally. Clean profile BUT very short half-life limits effectiveness compared to CJC-1295.

Key facts

Format
Lyophilized powder
Mechanism targets
Classification
Caution
Supply & nature
SecretagogueSecretagogue
FDA category
Approved (Geref — discontinued)

Evidence & standing

Evidence base
Approved therapeutic
Risk level
Standard
Best studies
4 references
  • Walker et al. (1990) JCEM 71:540-6 — GH response in adults
  • Vittone et al. (1997) Metabolism 46:89-96 — Elderly GH deficiency
  • Previously FDA APPROVED (Geref, 1997) — discontinued by manufacturer (not safety related)
  • Best-studied GH secretagogue for clinical use

Dosage & protocol

Typical dose
100-300mcg
Research range
100–300 µg
Cycle
Daily (night) — long-term
Onset
21 days first effects
Full effect
98 days
Half-life
~10-20min
~10-20 minutes (very short — limits efficacy)
Protocol

100-300mcg before bed SubQ. Some protocols use 200mcg 2x daily.

Time to effects

EARLY: 2-4 weeks

FULL: 12-16 weeks

Gentler onset than CJC-1295. The 'slow burn' GH peptide.

Week 2-4: Improved sleep quality.

Week 4-8: Subtle recovery and energy improvements.

Week 12-16: Cumulative anti-aging benefits.

Slower and milder than CJC-1295. Minimum commitment: 12 weeks. Best for conservative, long-term GH optimisation.

Recommended vial
  • 5mg vials

At 300mcg/day, 5mg = ~17 days ✓. Sermorelin is LESS stable (2-4 wk shelf life) so 5mg is ideal. 10mg risks degradation.

Reference figures only

Dosing reflects published laboratory protocols and is not guidance for use in any living subject.

Safety

Reversibility
Fully Reversible
Side effects

Flushing, headache, injection site pain/swelling (10-15%), dizziness, transient hyperactivity in children

Interactions

Glucocorticoids (↓response), somatostatin analogs, thyroid hormones, insulin

Do not combine
CJC-1295 DACCJC-1295 DAC CJC-1295 NO DACCJC-1295 NO DAC CJC-1295 NO DAC 5mg + Ipamorelin 5mg (Blend)CJC-1295 NO DAC 5mg + Ipamorelin 5mg (Blend) HGH 191 AA (97%)HGH 191 AA (97%) TesamorelinTesamorelin

Handle with research caution

  • Do NOT combine with exogenous HGH
  • Do NOT combine with CJC-1295 (same GHRH receptor — use one or the other)

Storage & handling

Lyophilised
12–24 months
2–8°C
Reconstituted
2–4 weeks
2–8°C

Videos & talks

Independent educational content from researchers, clinicians and science communicators — not affiliated with Pepnerd.

Educational resources only. Videos are independent third-party content. Pepnerd is not affiliated with these creators and does not endorse or make claims based on their content. All products are for in-vitro research.